

Therapeutic Use of the Newly Described “Artery of Qureshi”

Yousef Mohammad, MD, MSc, FAHA^{1*}

¹King Saud University, Riyadh, Saudi Arabia

To the editor:

I read with interest the article by Qureshi [1] regarding the description of artery to trigeminal nerve ganglion. The identification of artery of Qureshi [1] paves the way for intra-arterial delivery of therapeutic agents to the trigeminal nerve ganglion for treatment refractory trigeminal neuralgia [2]. The authors had previously described two cases with resolution of refractory headaches following intra-arterial injection of lidocaine and methyl-prednisolone into middle meningeal artery [3]. We are learning more about intra-arterial approaches to refractory headaches and trigeminal neuralgia and hope that such work continues to expand our therapeutic options.

It would be of interest to see if artery of Qureshi (to trigeminal nerve ganglion) has various morphological subtypes (single versus multiple small arteries) and what other normal variations exist between individuals.

References

1. Qureshi AI. Artery of trigeminal nerve ganglion. *J Vasc Interv Neurol* 2017;9:57–58.
2. Qureshi AI, et al. Intra-arterial modulation of the trigeminal nerve ganglion in patients with refractory trigeminal neuralgia. *J Neuroimaging* 2018;28:79–85.
3. Qureshi AI, et al. Effect of intra-arterial injection of lidocaine and methyl-prednisolone into middle meningeal artery on intractable headaches. *J Vasc Interv Neurol* 2014;7:69–72.